paclitaxel-coated devices

Long-Term SAFE-PAD Data Reassure on Mortality After Paclitaxel-Coated Femoropopliteal Interventions

By MedXY 05/06/2026

In Medicare patients undergoing femoropopliteal revascularization, drug-coated devices were not associated with higher long-term mortality, supporting the safety of paclitaxel-coated technology after years of regulatory concern.

Cardiology news Specialties

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

By MedXY 09/17/2025

The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.

Cardiology news Specialties

Paclitaxel-Coated vs Uncoated Devices in Chronic Limb-Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial

By MedXY 09/17/2025

The SWEDEPAD 1 trial evaluated paclitaxel-coated versus uncoated devices for infrainguinal revascularisation in chronic limb-threatening ischaemia, finding no significant reduction in major amputations or mortality over a median 2.7-year follow-up.